Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-05.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
Immunomodulation Therapy in Children with Aplastic Anemia.

Journal of the Korean Pediatric Society 1990;33(2):170-177.
Published online February 28, 1990.
Immunomodulation Therapy in Children with Aplastic Anemia.
Won Suk Suh1, Ki Sik Min1, Woo Gun Choi1, Hack Ki Kim1, Kyoung Sn Lee1, Soon Yong Lee2
1Department of Pediatrics, Catholic University Medical College, Seoul, Korea.
2Department of Pediatrics, Inje Medical College, Pusan, Korea.
재생불량성 빈혈 환아에서의 면역조절 요법
서원석1, 민기식1, 최우건1, 김학기1, 이경수1, 이순용2
1가톨릭의과대학 소아과학교실
2인제대학교 의과대학 소아과학교실
Received: 7 July 1989   • Accepted: 26 September 1989
Thirty patients with aplastic anemia(fifteen severe aplastic anemia and fifteen moderate aplastic anemia) treated with antilymphocyte globulin and cyclosporin A as a kind of immunomodulation therapy were studied by analysing hematologic reseponses and complications. The results were as follows; 1) Nineteen out of thirty patients (63.3%) treated with anti lymphocyte globulin plus cyclosporin A showed responses (complete response of 33.3%, partial response of 30.0%). 2) Hematologic responses according to the severity of disease were shown in six out of fifteen severe aplastic anemia patients(40.0%;complete response of 13.4%, partial response of 26.6%) and in thirteen out of fifteen moderate aplastic anemia patients(86.6%complete response of 53.3%, Partial response of 33.3%). 3) Hematologic responses according to the difference of sex were shown in nine out of seventeen male patients(52.9%;complete response of 17.6%, partial response of 35.3%) and ten out of thirteen female patients(77.0 % complete response of 53.8%, partial response of 23.2%). 4) Most of the responses were noticed between 2 months and 6 months(mean:3.6 months) after the initiation of therapy;earlist at 2 months, latest at 6 months. 5) The complications of therapy were thrombocytopenia, hypertension, fever and rash etc., Although this study is preliminary, our data suggest that antilymphocyte globulin plus cyclosporin A may be useful therapeutic modality for the patients with severe aplastic anemia who can not be the candidate for bone marrow transplantation and moderate aplastic anemia.
Key Words: Aplastic anemia, Immunomodulation

METRICS Graph View
  • 934 View
  • 2 Download